Accordingly, the new generation of breakpoint cluster region (BCR)-ABL inhibitors (Dasatinib and Nilotinib) is currently being used for the treatment of systemic sclerosis [119,120,121]. The gene discussed is BCR; the disease is systemic sclerosis.